Latest news and press releases about Predictive Oncology Inc. (POAI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline.
Price
| Price | $4.91 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.84 |
| EV / EBITDA | -0.50 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -488.50% |
| Return on Invested Capital | -57.56% |
| Return on Assets | -440.73% |
| Gross Margin | 7.15% |
| Operating Margin | -1483.87% |
| Net Margin | -7242.42% |
Related companies: AIM · AMIX · BNGO · CYCN · GBS · HSCS · KTTA
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of POAI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks